2019
- What recent changes may influence pharmacotherapy of community-acquired pneumonia?
- What are the most recent updates from the Advisory Committee on Immunizations Practices regarding HPV vaccination?
- What guidance is available for tapering long-term opioid analgesics?
- Update: What information has been yielded from the cardiovascular safety studies on new anti-hyperglycemic agents?
- What criteria exist to suggest use of denosumab for the treatment of hypercalcemia of malignancy over other calcium reducing options?
- What is the pharmaceutical contaminant N-nitrosodimethylamine (NDMA) and what risk does it pose to humans?
- What is the clinical relevance of the clopidogrel/proton pump inhibitor (PPI) interaction?
- What is the comparative diagnostic value of the novel somatostatin analog radiotracers for SSRT PET?
- What data are available regarding short versus long duration of antibiotic treatment for uncomplicated Enterobacteriaceae bacteremia?
- What evidence supports the use of oral factor Xa inhibitors for VTE prevention in patients with cancer?
- Do psychostimulants cause tics?
- Is there evidence to support the use of echinocandins for urinary tract infection?
- What are alternatives to erythromycin ophthalmic ointment for prophylaxis of gonococcal ophthalmia neonatorum?
- Update: Does extended infusion piperacillin-tazobactam (Zosyn) improve clinical outcomes?
- Is there literature to support the combined use of lactulose and rifaximin for the treatment of acute overt hepatic encephalopathy?
- What is the evidence for rectal indomethacin for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis?
- What is the optimal duration of antimicrobial surgical site infection prophylaxis in cardiac surgery?
- What evidence is available for the use of capsaicin in cannabinoid hyperemesis syndrome?
- What is the evidence for using haloperidol for migraines in the emergency department?
- Update: What is the safety information available on the use of DOACs in patients with renal impairment?
- Is intravenous ketamine effective for treatment of headache disorders in the emergency department?
- Does elevated INR in hospitalized patients with chronic liver disease suggest that anticoagulation is not necessary?
- Is ticagrelor the optimal antiplatelet for patients with peripheral artery disease?
- Is there a role for newer cation exchange resins (ie, patiromer and sodium zirconium cyclosilicate) in the emergency management of hyperkalemia?
- Update: What data are available to direct dosing of intravenous immunoglobulin G based on total versus ideal or adjusted body weight?
- What evidence exists to support the use of nebulized sodium bicarbonate as a mucolytic in hospitalized patients?
- What is the available literature regarding use of KCentra® (Four Factor Prothrombin Complex Concentrate) (4F-PCC) for the treatment of coagulopathies and acute hemorrhage in patients with liver disease who are not receiving concomitant anticoagulation therapy?
- What data exist for the use of tolvaptan beyond 30 days in the setting of hyponatremia?
- What are anesthesia safety considerations related to patients taking cannabis?
- Can alteplase be used to clear occluded chest tubes?
- What is the latest evidence on alternatives to magnesium sulfate in patients with preeclampsia and eclampsia?
- What are the Infectious Diseases Society of America recommendations for the diagnosis and management of seasonal influenza?
- What clinical data are available comparing nicardipine to clevidipine in acute ischemic stroke?
- What evidence is available to support the use of N-acetylcysteine for impulse control disorders?
- What evidence supports the use of direct-acting oral anticoagulants in patients with cancer-related VTE?